1. Home
  2. HBNC vs TYRA Comparison

HBNC vs TYRA Comparison

Compare HBNC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Bancorp Inc.

HBNC

Horizon Bancorp Inc.

HOLD

Current Price

$17.29

Market Cap

883.5M

Sector

Finance

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$21.50

Market Cap

844.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBNC
TYRA
Founded
1873
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
883.5M
844.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HBNC
TYRA
Price
$17.29
$21.50
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$19.67
$31.20
AVG Volume (30 Days)
236.6K
496.7K
Earning Date
01-21-2026
11-05-2025
Dividend Yield
3.69%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$51.78
N/A
Revenue Next Year
$7.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.91
N/A
52 Week Low
$12.70
$6.42
52 Week High
$18.54
$22.83

Technical Indicators

Market Signals
Indicator
HBNC
TYRA
Relative Strength Index (RSI) 65.96 68.26
Support Level $16.95 $20.08
Resistance Level $17.61 $22.83
Average True Range (ATR) 0.37 1.61
MACD 0.11 0.12
Stochastic Oscillator 85.08 84.28

Price Performance

Historical Comparison
HBNC
TYRA

About HBNC Horizon Bancorp Inc.

Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: